16 January 2025
Clean Power Hydrogen plc
("CPH2", the "Company" or the "Group")
Issue of Ordinary Shares
CPH2, the UK-based green hydrogen technology and manufacturing company that has developed the IP-protected Membrane-Free Electrolyser ("MFE"), is pleased to announce that it has issued 536,666 new Ordinary Shares (the "New Shares") at an issue price of 7.5 pence per share to satisfy additional demand following the recent fundraising announced on 18 December 2024. The New Shares are being issued under its existing authorities. The Company does not intend to issue any further shares as part of the fundraising.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM. Admission is expected to become effective in respect of, and dealings on AIM are expected to commence in, the New Shares, at 8:00 a.m. on 20 January 2025.
Following Admission of the New Shares, the Company will have 354,424,187 Ordinary Shares in issue with the Company holding no Ordinary Shares in treasury. Therefore, the total number of voting rights will also be 354,424,187. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Clean Power Hydrogen plc | via Camarco |
Jon Duffy, Chief Executive Officer | |
James Hobson, Chief Financial Officer | |
| |
| |
Cavendish Capital Markets Limited - NOMAD & Broker | |
Neil McDonald | +44 (0)131 220 9771 |
Peter Lynch | +44 (0)131 220 9772 |
Adam Rae | +44 (0)131 220 9778 |
| |
| |
Camarco PR | +44 (0)20 3757 4980 |
Billy Clegg | |
Owen Roberts | |
Kirsty Duff
| |
Further information on the Company can be found on its website at: https://www.cph2.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.